Christoph Herbel(Miltenyi Biotec) | 공간생물학을 통한 난소암의 Novel Folate Receptor 1-Directed CAR T 세포 전임상 평가 [밀테니바이오텍코리아] | 웨비나

기업기술웨비나 개최완료

공간생물학을 통한 난소암의 Novel Folate Receptor 1-Directed CAR T 세포 전임상 평가 [밀테니바이오텍코리아]

조회1645

2024년 05월 28일 (화) 오후 03시
Christoph Herbel(Miltenyi Biotec)

개요

							Preclinical Evaluation of Novel Folate Receptor 1-Directed CAR T Cells for Ovarian Cancer via spatial biology
공간생물학을 통한 난소암의 Novel Folate Receptor 1-Directed CAR T 세포 전임상 평가


Ovarian cancer is a devastating disease due to the late diagnosis of advanced stage disease and high recurrence rates. Thus, new long-lasting, efficient drugs are needed. Since chimeric antigen receptor (CAR)-expressing T cell treatments have led to efficient and persisting anti-tumor responses, our study aimed to design and characterize CAR T cells targeting ovarian cancer. We confirmed folate receptor 1 (FOLR1) as a promising tumor-associated antigen in ovarian cancer patient samples with help of the ultra-high-plex spatial biology MACSima platform. After designing a library of FOLR1-directed CAR T cells, their functionality and specificity were assessed in vitro against cell lines as well as in vivo in a mouse model of ovarian cancer. Finally, we selected a lead candidate for further characterization. The anti-FOLR1 CAR was successfully tested, including assays, reflecting the solid tumor microenvironment. These characteristics will support the clinical translation of our new FOLR1-specific CAR T cell asset.

세미나 영상

개최 완료